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Abstract
Since its first description in 1968, IgA nephropathy has remained the most
common form of primary glomerulonephritis leading to chronic kidney disease
in developed countries. The clinical progression varies, and consequent
end-stage renal disease occurs in 30% to 40% of patients 20 to 30 years after
the first clinical presentation. Current data implicate overproduction of
aberrantly glycosylated IgA1 as being pivotal in the induction of renal injury.
Effective and specific treatment is still lacking, and new therapeutic approaches
will be developed after better understanding the disease pathogenesis.
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Introduction
IgA nephropathy (IgAN) remains the most common primary 
glomerulonephritis worldwide. Other than diabetic nephropathy, 
IgAN remains the next important health-care issue in nephrology 
as it often affects young adults and the nephropathy pursues a slow 
but relentless clinical course. Consequent end-stage renal disease 
(ESRD) occurs in 30% to 40% of patients within 20 to 30 years 
after clinical presentation. The kidney is a target of injury in IgAN, 
yet the primary defect originates from a systemic aberrant glyco-
sylation of O-linked glycans in the hinge region of IgA1, resulting 
in increased serum levels of galactose-deficient IgA1 (Gd-IgA1). 
As the immunochemical abnormality of IgA is not corrected by 
renal transplantation, not surprisingly IgAN can frequently recur in 
allograft. Effective and specific treatment for IgAN is still lacking.
Serum Gd-IgA1 levels are heritable in a dominant pattern with 
reduced penetrance, although most patients’ relatives who have high 
serum levels of Gd-IgA1 do not exhibit clinical manifestations of 
renal injury. IgAN may occur in either sporadic or familial pattern. 
Familial IgAN may have a poorer prognosis with an increased risk 
of progression to renal failure, but this is controversial. Patients with 
familial IgAN have increased serum levels of galactose-deficient 
macromolecular IgA1 as compared with patients with sporadic 
IgAN. Macromolecular IgA1 isolated from patients with familial 
IgAN has enhanced binding to mesangial cells in vitro. These obser-
vations support the notion that genetic factors are involved in the 
pathogenesis of familial, as well as sporadic, IgAN, and risk factors 
of multiple candidate genes have been identified in different ethnic 
groups. The goal of this review is to present the genetic data discov-
ered in the last decade, and discuss the treatment options in IgAN.
Genetic data
Epidemiological data support a strong genetic contribution to 
IgAN1. First, there are significant geographic and ethnic differ-
ences in the prevalence of IgAN; the highest frequency is in East 
Asians, and it is relatively common in Mediterranean countries 
and very uncommon in individuals of African ancestry2,3. Second, 
IgA1 glycosylation defects exhibit high heritability in relatives of 
familial IgAN patients4–6. Familial IgAN presenting as autosomal 
dominant transmission with incomplete penetrance has been well 
recognized1. Despite numerous efforts at gene mapping by using 
linkage approaches, Mendelian defects responsible for familial 
IgAN remain elusive unless large families are available for study. 
Earlier studies of IgAN families revealed four linked loci.
6q22-q23 (IGAN1) and 3p24-p23 loci were the first loci identi-
fied in linkage analysis of IgAN with a logarithm of the ratio of 
odds (LOD) score of 5.67. The study analyzed 24 Italian and six 
American families, suggesting another locus at 3p24-p23 with 
a maximum LOD score of 2.8. Next, 2q36 locus was revealed in 
a four-generation Canadian family of German-Austrian origin with 
14 affected and 11 unaffected members8. The pedigree is consistent 
with autosomal dominant inheritance. Parametric and non-parametric 
linkage analysis produced significant LOD scores according to 
standard criteria for Mendelian disease. Finally, a European IgAN 
consortium identified suggestive loci at 4q26-q31 (LOD score 
of 1.8) and 17q12-q22 (LOD score of 2.6) in 22 Italian families 
with 59 affected and 127 unaffected members. The loci were named 
IGAN2 and IGAN9. Intriguingly, these four loci have not been 
revealed in familial IgAN of other ethnicity10.
The genome-wide association study (GWAS) approach has emerged 
as a powerful alternative to family-based studies for complex traits 
and has been successfully applied to IgAN. The first GWAS for 
IgAN based on European patients11 was shortly followed by two 
larger studies performed in Chinese cohorts of Hans ethnicity12,13. 
Notably, all three studies consisted of a relatively small discov-
ery sample of 3,000 IgAN cases. Seven independent risk loci 
with genome-wide significance (P < 5 × 10-8) were identified and 
these loci cumulatively explained approximately 5% of the overall 
disease variance.
The IgAN risk allele frequencies correlate well with disease 
epidemiology3. Notably, East Asians with the highest prevalence 
of IgAN carry the highest average number of risk alleles, but IgAN 
is less common in Africans with the lowest burden of risk alleles. 
IgAN as a leading cause of ESRD is nearly 10-fold higher among 
US kidney patients with East Asian ancestry when compared with 
African Americans3. Since over 85% of the existing GWAS discov-
ery cohorts are ethnic Chinese, studies in other ethnicities (espe-
cially from Mediterranean countries and Australasia with moderate 
prevalence) are needed to understand genetic risk profiles among 
other populations.
Contrary to the genetic approaches using linkage studies, and 
GWAS that requires a large patient cohort of sporadic IgAN, Liu 
et al.14 studied 10 IgAN families of Han Chinese ethnicity by 
using exome sequencing techniques. IgAN families are enriched in 
genetic components predisposing individuals to the development of 
this disorder. The technique of exome sequencing allows the inter-
rogation of the whole exome to identify genes and gene variants 
that underlie both monogenic and complex diseases. Six deleterious 
variants in four genes associated with familial IgAN were discov-
ered. Of interest is the association of DEFA gene and the disease 
susceptibility in both sporadic and familial IgAN of Han Chinese 
ethnicity with different mutations14,15.
Through careful analysis and annotation of the detected loci, sev-
eral causal candidate genes have been prioritized, linking pathways 
involved in the pathogenesis of IgAN. The implicated pathways 
include (i) the antigen-processing and presentation pathway (three 
loci on chromosome 6p21 in the major histocompatibility complex 
[MHC] region), (ii) the mucosal immunity pathway (chromosomes 
22q12 HORMAD2 locus, 8p23 α-defensin [DEFA] locus, and 17p13 
TNFSF13 locus), and (iii) the alternative complement pathway 
(chromosome 1q32 complement factor H [CFH] locus)11–13.
(i) Antigen-processing and presentation pathway
All three GWASs of IgAN identified strong signals within the MHC 
region with three distinct susceptibility loci on chromosome 6p21: 
HLA-DRB1/DQB1, HLA-DPB1/DPB2, and TAP1/PSMB9. HLA-
DRB1-DQA1 and -DQB1 genes carry the strongest association, and 
the DQB1*0602-DRB1*1501 haplotype confers a highly protective 
effect12.
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The second distinct MHC locus was centered over the region of 
the HLA-DPA1, -DPB1, and -DPB2 genes (also encoding MHC-II 
molecules), but the causal variant at this locus and its involvement 
in IgAN are still not known. The third MHC locus contained the 
TAP1, TAP2, PSMB8, and PSMB9 genes. These genes play an 
important role in modulation of cytokine production and cytotoxic 
T-cell response through antigen processing for presentation by 
MHC-I molecules.
(ii) Mucosal immunity and regulation of IgA production
The clinical characteristic of synpharyngitic macroscopic hematu-
ria led to the hypothesis that defects in the regulation of local IgA 
response or abnormal mucosal antigen handling (or both) may trig-
ger IgAN16.
APRIL, a proliferation-inducing ligand, is the molecule involved 
in T cell-independent generation of IgA-secreting plasma cells as 
well as in the IgA1 to IgA2 class switching. A GWAS locus on 
chromosome 17p13 contains TNFSF13 that encodes APRIL. Serum 
levels of APRIL are elevated in some patients with IgAN17, and 
raised total serum IgA occurs with the 17p23 risk variant12. Overex-
pression of B-cell activation factor (BAFF), a related molecule with 
overlapping functions and receptors with APRIL, results in mesang-
ial IgA deposits in mice17. A recent study from Japan showed that 
treatment of the newly developed grouped ddY (gddY) mice with 
anti-APRIL antibody reduced serum IgA levels, glomerular IgA 
deposition, albuminuria, and renal damage18. These data suggest 
that APRIL and BAFF signaling may be involved in the pathogen-
esis of IgAN and that both may be potential therapeutic targets.
A locus on chromosome 22q12 also influences serum IgA levels 
and encompasses several genes, including the IL-6 family-encoding 
genes LIF and OSM11.
The DEFA gene cluster on chromosome 8p23 is the third IgAN 
GWAS locus implicated in mucosal immunity. The α-defensin gene 
family encodes small, structurally related peptides that are secreted 
at mucosal surfaces with microbiocidal and chemoattractant 
properties19. α-defensin 1, 3, and 4 (encoded by DEFA1, DEFA3, 
and DEFA4) are synthesized in neutrophils, whereas α-defensin 5 
and 6 (DEFA5 and DEFA6) are constitutively released by the intes-
tinal Paneth cells into the gut lumen. It remains unclear whether the 
IgAN risk allele in this region confers a risk haplotype due to exces-
sive copies of DEFA1/3 genes or variants of DEFA5/6 genes.
Lately, six new genome-wide significant associations—four in 
ITGAM, ITGAX, VAV3, and CARD9 and two new independent sig-
nals at HLA-DQB1 and DEFA—were identified in a GWAS examin-
ing 20,612 IgAN individuals of European and East Asian ancestry20. 
Most loci are directly associated with either risk of inflammatory 
bowel disease or maintenance of the intestinal epithelial barrier and 
response to mucosal pathogens. A possible role for host-intestinal 
pathogen interactions in shaping the genetic landscape of IgAN has 
been proposed.
(iii) Alternative complement pathway
A common deletion (deleting CFHR3 and CFHR1 genes), within 
the CFH locus on chromosome 1q32, was found to be protective 
against IgAN in a GWAS studying both European and Asian 
populations12. The CFH gene encodes Factor H (FH) that regu-
lates the alternative complement pathway. FH-related proteins 
(FHR1–5) are structurally similar to FH and are encoded by five 
genes (CFHR1-5) residing within the same genomic region. Given 
the high level of sequence similarity between CFH and CFHRs, 
these genes are believed to have originated through segmental 
duplications and are prone to recurrent structural rearrangements. 
CFHR3,1Δ is the most common variant; allelic frequency ranges 
from 0% to 5% in East Asians to 20% in Europeans and up to 50% 
in some African populations21. Each additional copy of CFHR3,1Δ 
reduces the risk of IgAN by approximately 40%12.
Treatment
General
Patients with minor urine abnormalities and normal blood pressure 
and glomerular filtration rate (GFR) usually do well and require 
only periodic monitoring, such as biennial clinic visits. For other 
patients, the therapeutic options are limited and include non- 
specific treatment to reduce proteinuria by renin-angiotensin sys-
tem (RAS) blockade and non-specific control of inflammation 
using fish oil and agents such as corticosteroids, cytotoxic agents, 
anti-metabolite, and immunomodulatory drugs.
Conventional therapy
Renin-angiotensin-aldosterone axis blockade. Evidence accu-
mulated from 56 studies and 2,838 participants showed that only 
anti-hypertensive drugs—mostly angiotensin-converting enzyme 
inhibitor (ACEI) or angiotensin receptor blocker (ARB)—provided 
useful intervention mainly by reducing proteinuria22. RAS block-
ers are often prescribed for patients with IgAN and proteinuria. In 
a meta-analysis of 585 patients from 11 randomized clinical trials 
(RCTs)23, significant renoprotection and reduction of proteinuria 
were achieved with an ACEI or ARB versus control. The benefi-
cial effects are promoted by concomitant dietary sodium and phos-
phate restriction. In addition, the efficacy of RAS blockade could 
be modified by ACE (I/D) gene polymorphisms such that, in the 
future, personalized medicine could be developed using pharma-
cogenomics data24.
Aliskiren is an oral direct renin inhibitor that has a theoretical basis 
for fully suppressing the RAS as ACEI or ARB treatment leads to a 
reactive increase in plasma renin activity. So far, the only two trials 
from Hong Kong showed an anti-proteinuric effect on top of ACEI 
or ARB therapy25,26. Patients with more advanced chronic kidney 
disease are prone to developing hyperkalemia. Long-term outcomes 
have not been reported.
Fish oil. The possible benefit of fish oil containing omega-3 
polyunsaturated fatty acid in the treatment of IgAN rests on reduc-
ing intra-renal inflammation by mitigating inflammatory cytokines 
and eicosanoids. However, the published reports failed to show con-
vincing benefits.
In the original Mayo Clinic multicenter study with 106 subjects27, 
fewer patients randomly assigned for fish oil treatment reached the 
end-point of at least a 50% rise in serum creatinine. Notably, nei-
ther this original study nor a subsequent trial showed a reduction of 
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proteinuria. Proteinuria is a key therapeutic target because it may 
itself cause renal injury, and its reduction correlates with preserva-
tion of renal function. A recent trial of 30 patients suggested that a 
RAS blocker combined with polyunsaturated fatty acids reduced 
proteinuria more than RAS blocker alone28. The KDIGO (Kidney 
Disease: Improving Global Outcomes) 2012 Clinical Practice 
Guidelines29 suggest optional use of fish oil in the treatment of 
patients with persistent proteinuria of more than 1 g/day, despite 
3 to 6 months of optimized supportive care including ACEI or 
ARBs and blood pressure control. Yet, the long-term benefits on 
preventing ESRD are uncertain.
Immunosuppressive therapy
As stated earlier, IgAN is an autoimmune kidney disease and hence 
immune modulation targeting the putative pathogenic pathways 
may alter the disease progression. To date, no medications have 
been approved by the US Food and Drug Administration specifi-
cally for IgAN. The availability of new agents with novel mech-
anisms and activities against the humoral immune response may 
allow targeted treatment. Herein, we examine the existing evidence 
for immunosuppressive therapy in IgAN.
Corticosteroids. Since early 1980, corticosteroids were often pre-
scribed to IgAN patients with moderate to severe persisting pro-
teinuria (variably defined as more than 0.5 to 1.0 g/day lasting for 
at least 3 months). A meta-analysis of nine randomized controlled 
trials (including 536 patients with urinary protein excretion of more 
than 1 g/day and normal renal function) suggested that high-dose 
and short-term corticosteroid therapy produced significant renal 
protection but that low-dose, long-term corticosteroid use did not30. 
The 2012 KDIGO Guidelines29 recommend that patients with per-
sistent proteinuria of more than 1 g/day despite adequate ACEI or 
ARB and blood pressure control and a GFR of more than 50 ml/min 
per 1.73 m2 receive a 6-month course of steroid therapy. A signifi-
cant knowledge gap thus existed because patients with an estimated 
GFR (eGFR) of 30 to 50 ml/min per 1.73 m2 have been excluded 
from virtually all major clinical trials. A recent retrospective analy-
sis of the European Validation Study of the Oxford Classification 
of IgAN (VALIGA) cohort of 1,147 patients (mostly white) may 
help to address this gap31. In the propensity score analysis, add-
ing corticosteroid to RAS blocker resulted in a better reduction of 
proteinuria, a slower rate of renal function decline, and increased 
renal survival in comparison with administering RAS blocker alone 
in two groups of patients with a similar risk profile of progression. 
These benefits extended to 115 patients with an eGFR of less than 
50 ml/min per 1.73 m2, and the benefits increased proportionally 
with the level of baseline proteinuria. However, the study is limited 
by its retrospective nature, unknown corticosteroid dosing regimens, 
frequent combination of corticosteroids with other immunosuppres-
sive therapies, the potential for unmeasured and selection bias, and 
the potential for selection of patients by the participating center32.
Two new trials were conducted to further address the therapeutic 
value of conventional corticosteroid. STOP-IgAN is a German trial 
that randomly assigned adults with an eGFR of at least 30 ml/min 
per 1.73 m2 and persistent proteinuria of more than 0.75 g per day 
despite 6 months of supportive care (in particular, blockade of the 
RAS to a target blood pressure of less than 125/75 mm Hg) to receive 
supportive care alone or supportive care plus immunosuppression 
(corticosteroids alone if eGFR was 60 to 89 ml/min per 1.73 m2 or 
in combination with cyclophosphamide for the initial 3 months, fol-
lowed by azathioprine if eGFR was 30 to 59 ml/min per 1.73 m2)33. 
During the run-in phase completed by 309 of 337 patients, pro-
teinuria decreased to less than 0.75 g per day in 30% of the subjects, 
who then became ineligible for random assignment. Of 154 patients 
who underwent random assignment and completed 3 years of treat-
ment, more patients in the immunosuppression group achieved full 
clinical remission (urine protein/creatinine of less than 0.2 g/g and 
reduction in eGFR of less than 5 ml/min per 1.73 m2), but there was 
no significant difference in the annual decline in eGFR between 
the two groups. Patients in the immunosuppression group had a 
significantly lower mean proteinuria level than those in the 
supportive-care group at 12 months after random assignment, but 
this difference disappeared at 36 months. The major conclusion 
was that the addition of immunosuppressive therapy to intensive 
supportive care did not significantly improve the outcome and may 
increase adverse effects. The study is limited by its open-label 
nature, relatively short duration of follow-up for the end-point of 
renal deterioration, the lack of histologic stratification for inclusion, 
and the questionable design of assigning steroid monotherapy to 
patients with an eGFR of more than 60 ml/min per 1.73 m2 and the 
addition of cyclophosphamide followed by azathioprine to patients 
with even lower eGFR. Finally, the findings could be conflicted by 
a relatively high proportion of subjects who were given combined 
ACEi and ARB treatment.
TESTING is another large multicenter, double-blinded, randomized, 
placebo-controlled trial in progress. TESTING started recruitment 
in 2012 internationally to investigate the efficacy of oral methyl-
prednisolone versus placebo in IgAN. The study includes patients 
with a wide range of eGFR values, from 20 to 90 ml/min per 1.73 m2.
Cyclophosphamide in combination with corticosteroids. In 
Caucasian subjects, cyclophosphamide plus corticosteroid therapy 
may benefit patients at high risk of developing ESRD, namely 
those with glomerular crescents and rapidly progressive clinical 
course34,35. In Chinese patients, crescentic IgAN carries a poor prog-
nosis. Amongst 113 such patients from eight centers across China, 
no benefit was observed in the renal survival when cyclophospha-
mide was added to pulse corticosteroid therapy36. The 2012 KDIGO 
Guidelines29 suggest the use of corticosteroids and cyclophospha-
mide in patients with IgAN and rapidly progressive crescentic 
IgAN, analogous to the treatment of anti-neutrophil cytoplasmic 
antibody (ANCA) vasculitis, but this is not based on evidence from 
clinical trials.
Tonsillectomy in combination with corticosteroids. The practice of 
tonsillectomy in IgAN (mainly in Japan) is based on observation of 
disease activation, manifested as macroscopic hematuira and renal 
dysfunction following upper respiratory tract infection. Recently, 
a gene encoding glycosyltransferase involved in glycosylation of 
O-glycan in IgA molecules has been demonstrated to be downregu-
lated in tonsillar B lymphocytes from patients with IgAN37. Outside 
Japan, the benefits of tonsillectomy have not been documented. 
A meta-analysis of seven non-randomized studies (mostly from 
Japan) comprising 858 patients (534 underwent tonsillectomy and 
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324 did not) showed that tonsillectomy combined with either stand-
ard or pulse corticosteroid treatment, but not tonsillectomy or cor-
ticosteroid treatment alone, resulted in higher remission rates with 
favorable long-term outcome38. Lately, a multicenter randomized 
controlled trial from Japan showed that tonsillectomy combined 
with steroid pulse therapy has no beneficial effect over steroid 
pulses alone to attenuate hematuria and to increase the incidence 
of clinical remission39. Although the anti-proteinuric effect was 
greater in combined therapy, the difference was marginal. Finally, 
a recent meta-analysis of 14 studies (also mostly from Japan) also 
found positive effects of tonsillectomy plus pulse or conventional 
steroid40. The 2012 KDIGO Guidelines29 suggest that tonsillectomy 
not be performed for IgAN.
Azathioprine. A recent moderately large-scale study randomly 
assigned 207 patients to either corticosteroids alone (n = 106) or in 
combination with azathioprine (n = 101) for 6 months41. Azathio-
prine conferred no additional benefit but resulted in more adverse 
events, namely hepatotoxicity, anemia, and gastrointestinal symp-
toms. The 2012 KDIGO Guidelines29 do not recommend the use of 
azathioprine in IgAN.
Mycophenolate mofetil. Three studies in Chinese patients showed 
a benefit of mycophenolate mofetil (MMF): (i) In 62 patients with 
severe IgAN and urinary protein of more than 2 g/day, the MMF 
group showed significant improvement in proteinuria and serum 
lipids than the prednisone group42. (ii) Among 40 Chinese patients 
with mild tubulointerstitial lesions with persistent proteinuria of 
more than 1 g/day despite full RAS blockade, MMF treatment 
for 6 months resulted in significant reduction in proteinuria43 and 
improved renal survival at 6-year follow-up44. (iii) In a study compar-
ing therapy with MMF/prednisone and cyclophosphamide/prednisone 
for severe IgAN45, the former regimen achieved a higher remission 
rate with better reduction of proteinuria and improvement of renal 
function and less adverse effects.
In contrast, three studies in Caucasians showed mixed results: 
(i) Among 34 Belgian patients with impaired renal function, his-
tologic unfavorable criteria and arterial hypertension, a combina-
tion of salt restriction, ACEI therapy and high-dose MMF failed to 
demonstrate a better beneficial effect after 3 years of evaluation46. 
(ii) In an American study that recruited patients with even more 
advanced renal insufficiency, a worse outcome occurred with MMF 
as a “salvage” therapy47. (iii) In another Italian study, a subset of 
IgAN patients with florid glomerular changes treated with MMF 
and corticosteroids showed remission of proteinuria and reversal of 
progressive renal failure48.
Given that these mixed results occurred across different ethnic 
groups and that none of these studies was adequately powered to 
provide a definitive answer, the 2012 KDIGO Guidelines29 sug-
gest not using MMF in IgAN. More recently, one trial conducted 
in 52 children, adolescents, and adults with IgAN in the US and 
Canada was terminated prematurely as MMF did not reduce 
proteinuria49. Patients received lisinopril (or losartan) plus a highly 
purified omega-3 fatty acid for 3 months during run-in, and only 
those with a persistent urinary albumin/creatinine ratio of at least 
0.6 g/g (males) or at least 0.8 g/g (females) were randomly assigned.
Novel therapies
Increased knowledge on the pathogenetic mechanisms of IgAN, 
particularly on the role of mucosal immunity and B-cell activation, 
has provided the impetus for several new phase II/III clinical trials. 
None of these have reached any conclusions yet.
Enteric budesonide. NEFIGAN is a phase IIb trial that was started 
in 2012 to evaluate the efficacy and safety of an enteric budeso-
nide delivered specifically to the ileocecal Peyer’s patches in 
primary IgAN across 10 European countries. Preliminary study 
demonstrated a reduction of proteinuria by 23% and a modest 
improvement of eGFR by 8% in 16 patients (proteinuria of more 
than 0.5 g/day and serum creatinine of less than 200 μmol/l) after 
6 months of enteric budesonide, followed by 3 months of further 
observation50. The study was completed in September 2015 and 
found encouraging results in terms of proteinuria reduction and sta-
bilization of renal function at 9 months (ASN Kidney Week 2015).
B-cell depletion/inhibition. Blisibimod is a selective peptibody 
antagonist of BAFF that can be administered subcutaneously. 
BRIGHT-SC (Blisibimod Response in IgAN Following At-Home 
Treatment by Subcutaneous Administration) began in 2013 and is 
currently recruiting patients in Asia and Europe.
Spleen tyrosine kinase (Syk) inhibition. An important molecule 
within an intracellular signaling pathway activated upon ligation 
of the B-cell receptor is Syk, which mediates maturation and sur-
vival of the B-cell lineage. Pharmacological inhibition of Syk, or 
its knockdown by small interfering RNA (siRNA), significantly 
reduced cellular proliferation and the synthesis of pro-inflammatory 
mediators in human mesangial cells exposed to IgA1 from patients 
with IgAN51. SIGN (Syk Inhibition for Glomerulonephritis), a mul-
ticenter trial, started recruitment in 2014 globally to evaluate the 
efficacy of fostamatinib (a selective oral Syk inhibitor) in patients 
with IgAN.
Proteasomal inhibition. There is preliminary evidence for a role of 
increased immunoproteasome activity in IgAN52. A single-center, 
open-label, exploratory study examining the effects of bortezomib 
(Velcade) in IgAN was started in 2010 in the US.
Conclusions
Despite a better understanding of the immunochemical nature of 
aberrantly glycosylated IgA1 and the genetic risk profile of IgAN, 
the key issue of how disease can be triggered following recurrent 
mucosal infection remains unknown. Specific treatment is lacking. 
Diagnosis by a non-invasive method such as disease biomarkers 
without invasive renal biopsy will allow increased disease detection 
rate and early treatment intervention.
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